

# CASE BASED LEARNING .....

## Systolic murmur in an asymptomatic 70 year old man

P Paramsothy, CM Otto, Division of Cardiology, University of Washington, Seattle, USA  
Correspondence to: Professor Catherine M Otto; cotto@u.washington.edu

A 70 year old man with hypertension underwent echocardiography for an asymptomatic murmur and was found to have aortic valve sclerosis. Over the next eight years, annual echocardiography showed progressive valve calcification with an increase in transaortic velocity and pressure gradient and a decrease in valve area. He eventually developed decreased exercise tolerance and was referred for aortic valve replacement.

The purpose of this interactive case presentation is to illustrate the diagnosis and clinical implications of aortic valve sclerosis and the progression of sclerosis to significant stenosis, and its appropriate diagnosis and management.

The purpose of this interactive case presentation is to illustrate:

- The clinical significance of aortic valve sclerosis
- The clinical factors associated with aortic valve sclerosis
- The diagnosis of aortic valve stenosis
- The natural history of aortic stenosis
- The physical signs and echo cardiographic features of severe aortic stenosis

This interactive case history is hosted on BMJ Learning—the best available learning website for medical professionals from The BMJ Group.

To access the interactive case, please use **[Take this module on BMJ Learning]** link from the online article content box or table of contents.

### References

- 1 **Otto CM**. Why is aortic sclerosis associated with adverse clinical outcomes? *J Am Coll Cardiol* 2004;**43**:176–7.
- 2 **Stewart BF**, Siscovick D, Lind BK, *et al*. Clinical factors associated with calcific aortic valve disease. *J Am Coll Cardiol* 1997;**29**:630–4.
- 3 **Otto CM**, Lind BK, Kitzman DW, *et al*. Association of aortic valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med* 1999;**341**:142–7.
- 4 **Otto CM**, Kuusisto J, Reichenbach DD, *et al*. Characterization of the early lesion of degenerative valvular aortic stenosis. *Circulation* 1994;**90**:844–53.
- 5 **Chandra HR**, Goldstein JA, Choudhary N, *et al*. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. *J Am Coll Cardiol* 2004;**43**:169–75.

- 6 **Olsson M**, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. *Atheroscler Thromb Vasc Biol* 1999;**19**:1218–22.
- 7 **O'Brien KD**, Shavelle DM, Caulfield MT, *et al*. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. *Circulation* 2002;**106**:2224–30.
- 8 **Rajamannan NM**, Subramaniam M, Rickard D, *et al*. Human aortic valve calcification is associated with an osteoblast phenotype. *Circulation* 2003;**107**:2181–4.
- 9 **Novaro GM**, Sachar R, Pearce GL, *et al*. Association between apolipoprotein e alleles and calcific valvular disease. *Circulation* 2003;**108**:1804–8.
- 10 **Ortlepp JR**, Hoffmann R, Ohme F, *et al*. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. *Heart* 2001;**85**:635–8.
- 11 **Agmon Y**, Khandheria BK. Aortic valve sclerosis and aortic atherosclerosis: different manifestation so the same disease. *J Am Coll Cardiol* 2001;**38**:827–34.
- 12 **Poggianti E**, Venneri L. Aortic valve sclerosis is associated with systemic endothelial dysfunction. *J Am Coll Cardiol* 2003;**41**:136–41.
- 13 **Munt B**, Legget ME, Kraft CD, *et al*. Physical examination in valvular aortic stenosis: correlation with stenosis severity and prediction of clinical outcome. *Am Heart J* 1999;**137**:298–306.
- 14 **Faggiano P**, Antonini-Canterin F, Erlicher A, *et al*. Progression of aortic valve sclerosis to aortic stenosis. *Am J Cardiol* 2003;**91**:99–101.
- 15 **Cosmi JE**, Kort S, Tunick PA, *et al*. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. *Arch Intern Med* 2002;**162**:2345–7.
- 16 **Otto CM**, Burwash IG, Legget ME, *et al*. Prospective study of asymptomatic valvular aortic stenosis. *Circulation* 1997;**95**:2262–70.
- 17 **Rosenhek R**, Binder T, Porenta G, *et al*. Predictors of outcome in severe, asymptomatic aortic stenosis. 2000;**343**:611–17.
- 18 **Rosenhek R**, Klaar U, Schemper M, *et al*. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. *Eur Heart J* 2004;**25**:199–205.
- 19 **Carabello BA**. Clinical practice: aortic stenosis. *N Engl J Med* 2002;**346**:677–82.
- 20 **Berlger-Klein J**, Klaar U, Heger M, *et al*. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. *Circulation* 2004;**109**:2302–8.
- 21 **Gerber IL**, Stewart RAH, Legget ME, *et al*. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. *Circulation* 2003;**107**:1884–90.
- 22 **Novaro GM**, Tiong IY, Pearce GL, *et al*. Effect of hydroxymethyl-glutaryl coenzyme reductase inhibitors on the progression of calcific aortic stenosis. *Circulation* 2001;**104**:2205–9.
- 23 **Bellamy MF**, Pellikka PA, Klarich KW, *et al*. Association of cholesterol levels, hydroxymethyl-glutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. *J Am Coll Cardiol* 2002;**40**:1723–30.
- 24 **Pohle K**, Maffert R, Ropers D, *et al*. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. *Circulation* 2001;**104**:1927–32.
- 25 **Shavelle DM**, Takasu J, Budoff MJ, *et al*. HMG CoA reductase inhibitor (statin) and aortic valve calcium. *Lancet* 2002;**359**:1125–6.